top
Please input keywords
OK
Database
News events
Contact us
EN
CN
JP
KR
About us
Introduction
History
Management team
Culture
Social Responsibility
Join us
Antibody Assets
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
Animal Models
Pharmacology Service
Gene Editing
Collaborations
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
News events
Downloads
Poster Downloads
Media Center
News
Events
Webinar
Publication
Downloads
Poster Downloads
Brochure
2023
AACR 2023: Novel Humanized CD36 Mouse Model for Therapeutic Studies
2023
AACR 2023: Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution
2023
AACR 2023: Development of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution
2022
PEGS-EU 2022:YH013, A Fully-human EGFR x MET Bispecific ADC Exhibits Outstanding Specificity and Anti-tumor Efficacy
2022
PEGS-EU 2022:1C3—A Differentiated Non-Blocking Agonist TNFR2 Antibody for Cancer Immunotherapy
2022
PEGS-EU 2022:A Novel TCR-mimic Fully Human Antibodies Discovery Platform
2022
World ADC San Diego2022丨YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy
2022
ASCO 2022: A phase I open-label dose escalation of YH003 (CD40 mAb) in combination with toripalimab (PD-1 mAb) in patients with advanced solid tumors
2022
ASCO 2022: A first-in-human phase I dose escalation of YH001 (CTLA-4 mAb) in combination with PD-1 mAb in patients with advanced solid tumors
1
…
5
6
7
8
9
…
14
GO
